| MARGARET A. ALEXANDER |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
1,435,000 |
1,435,000 |
26 Feb 2026 |
Direct |
| STELIOS PAPADOPOULOS |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
65,000 |
65,000 |
26 Feb 2026 |
Direct |
| Kevin Joseph Fitzgerald |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
65,000 |
65,000 |
26 Feb 2026 |
Direct |
| JEREMY M. LEVIN |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
957,000 |
957,000 |
26 Feb 2026 |
Direct |
| Bart Friedman |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
65,000 |
65,000 |
26 Feb 2026 |
Direct |
| Barbara Gayle Duncan |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
65,000 |
65,000 |
26 Feb 2026 |
Direct |
| Karen Bernstein |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
65,000 |
65,000 |
26 Feb 2026 |
Direct |
| Jeffrey A. Rona |
OVID |
Common Stock |
Award |
77.2% |
|
|
68,125 |
156,313 |
26 Feb 2026 |
Direct |
| Jeffrey A. Rona |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
408,750 |
408,750 |
26 Feb 2026 |
Direct |
| MARGARET A. ALEXANDER |
OVID |
Common Stock |
Sale |
-15.9% |
$16,901 |
$1.45 |
-11,656 |
61,750 |
23 Feb 2026 |
Direct |
| Jeffrey A. Rona |
OVID |
Common Stock |
Sale |
-8.83% |
$12,384 |
$1.45 |
-8,541 |
88,188 |
23 Feb 2026 |
Direct |
| MARGARET A. ALEXANDER |
OVID |
Employee Stock Option (right to buy) |
Award |
|
|
|
890,000 |
890,000 |
04 Jan 2026 |
Direct |
| JEREMY M. LEVIN |
OVID |
Common Stock |
Conversion of derivative security |
1.96% |
|
|
71,000 |
3,687,715 |
15 Dec 2025 |
Direct |
| JEREMY M. LEVIN |
OVID |
Series B Convertible Preferred Stock |
Conversion of derivative security |
-100% |
|
|
-71 |
0 |
15 Dec 2025 |
Direct |
| JEREMY M. LEVIN |
OVID |
Series B Warrant (right to buy) |
Purchase |
|
|
|
35,500 |
35,500 |
11 Dec 2025 |
Direct |
| JEREMY M. LEVIN |
OVID |
Series A Warrant (right to buy) |
Purchase |
|
|
|
47,333 |
47,333 |
11 Dec 2025 |
Direct |
| JEREMY M. LEVIN |
OVID |
Series B Convertible Preferred Stock |
Purchase |
|
|
|
71 |
71 |
11 Dec 2025 |
Direct |
| Takeda Pharmaceutical Co Ltd |
OVID |
Common Stock |
Conversion of derivative security |
21.7% |
|
|
1,250,000 |
7,000,000 |
08 Dec 2025 |
See Explanation of Responses |
| Takeda Pharmaceutical Co Ltd |
OVID |
Series A Convertible Preferred Stock |
Conversion of derivative security |
-100% |
|
|
-1,250 |
0 |
08 Dec 2025 |
See Explanation of Responses |
| STELIOS PAPADOPOULOS |
OVID |
Stock Option (right to buy) |
Award |
|
|
|
90,000 |
90,000 |
03 Mar 2025 |
Direct |
| MARGARET A. ALEXANDER |
OVID |
Common Stock |
Sale |
-6.71% |
$2,956 |
$0.5600 |
-5,279 |
73,406 |
26 Feb 2025 |
Direct |
| Jeffrey A. Rona |
OVID |
Common Stock |
Sale |
-5.43% |
$2,185 |
$0.5600 |
-3,902 |
67,973 |
26 Feb 2025 |
Direct |
| Kevin Joseph Fitzgerald |
OVID |
Stock Option (right to buy) |
Award |
|
|
|
45,000 |
45,000 |
20 Feb 2025 |
Direct |
| Bart Friedman |
OVID |
Stock Option (right to buy) |
Award |
|
|
|
45,000 |
45,000 |
20 Feb 2025 |
Direct |
| Barbara Gayle Duncan |
OVID |
Stock Option (right to buy) |
Award |
|
|
|
45,000 |
45,000 |
20 Feb 2025 |
Direct |
| Karen Bernstein |
OVID |
Stock Option (right to buy) |
Award |
|
|
|
45,000 |
45,000 |
20 Feb 2025 |
Direct |
| JEREMY M. LEVIN |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
1,650,000 |
1,650,000 |
20 Feb 2025 |
Direct |
| Jeffrey A. Rona |
OVID |
Common Stock |
Award |
155.6% |
|
|
43,750 |
71,875 |
20 Feb 2025 |
Direct |
| Jeffrey A. Rona |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
262,500 |
262,500 |
20 Feb 2025 |
Direct |
| MARGARET A. ALEXANDER |
OVID |
Common Stock |
Award |
125.2% |
|
|
43,750 |
78,685 |
20 Feb 2025 |
Direct |
| MARGARET A. ALEXANDER |
OVID |
Employee Stock Option (Right to Buy) |
Award |
|
|
|
262,500 |
262,500 |
20 Feb 2025 |
Direct |
| MARGARET A. ALEXANDER |
OVID |
Common Stock |
Purchase |
24.2% |
$4,971 |
$0.7300 |
6,810 |
34,935 |
27 Jan 2025 |
Direct |
| Kevin Joseph Fitzgerald |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
90,000 |
90,000 |
12 Dec 2024 |
Direct |
| Bart Friedman |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
90,000 |
90,000 |
12 Dec 2024 |
Direct |
| Barbara Gayle Duncan |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
90,000 |
90,000 |
12 Dec 2024 |
Direct |
| Karen Bernstein |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
90,000 |
90,000 |
12 Dec 2024 |
Direct |
| MARGARET A. ALEXANDER |
OVID |
Employee Stock Option (right to buy) |
Award |
|
|
|
140,000 |
140,000 |
09 Sep 2024 |
Direct |
| Jeffrey A. Rona |
OVID |
Employee Stock Option (right to buy) |
Award |
|
|
|
315,000 |
315,000 |
30 Jul 2024 |
Direct |
| JEREMY M. LEVIN |
OVID |
Common Stock |
Purchase |
0.51% |
$50,364 |
$2.76 |
18,248 |
3,616,715 |
18 Mar 2024 |
Direct |
| Jason Tardio |
OVID |
Common Stock |
Award |
|
|
|
28,125 |
28,125 |
22 Feb 2024 |
Direct |
| Jason Tardio |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
168,750 |
168,750 |
22 Feb 2024 |
Direct |
| Jeffrey A. Rona |
OVID |
Common Stock |
Award |
|
|
|
28,125 |
28,125 |
22 Feb 2024 |
Direct |
| Jeffrey A. Rona |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
168,750 |
0 |
22 Feb 2024 |
Direct |
| Robert Michael Poole |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
30,000 |
30,000 |
22 Feb 2024 |
Direct |
| Thomas Michael Perone |
OVID |
Common Stock |
Award |
|
|
|
28,125 |
28,125 |
22 Feb 2024 |
Direct |
| Thomas Michael Perone |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
168,750 |
168,750 |
22 Feb 2024 |
Direct |
| JEREMY M. LEVIN |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
700,000 |
700,000 |
22 Feb 2024 |
Direct |
| Bart Friedman |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
30,000 |
30,000 |
22 Feb 2024 |
Direct |
| Kevin Joseph Fitzgerald |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
30,000 |
30,000 |
22 Feb 2024 |
Direct |
| Barbara Gayle Duncan |
OVID |
Stock Option (Right to Buy) |
Award |
|
|
|
30,000 |
30,000 |
22 Feb 2024 |
Direct |